Current methods in treating early-onset<unk>  follow a similar approach to the treatment of adult<unk> . Although methods of treatment for<unk>  are largely understudied, the use of antipsychotic medicine is normally the primary line of treatment in addressing signs in<unk>  diagnoses. Contemporary practices of<unk>  treatment are multidisciplinary, recuperation oriented, and consist of medications, with psychosocial interventions that include familial support systems. However, research has shown that atypical antipsychotics may be preferable because they cause less short-term side effects. When weighing treatment options, it is necessary to consider the adverse effects, such as metabolic syndrome, of various medications used to treat<unk>  and the potential implications of these effects on development. A 2013 systematic review compared the efficacy of atypical antipsychotics versus typical antipsychotics for adolescents: + Atypical compared with typical antipsychotics (only short term) Summary There is not any convincing evidence suggesting that atypical antipsychotic medications are superior to the older typical medications for the treatment of adolescents with psychosis. However, atypical antipsychotic medications may be more acceptable because fewer symptomatic adverse effects are seen in the short term. Little evidence is available to support the superiority of one atypical antipsychotic medication over another. Outcome Findings in words Findings in numbers Quality of evidence Global state Worse or no improvement There is no clear difference between the newer atypical antipsychotic drugs and the typical drugs for this global outcome. These findings are based on data of low quality. RR 3.3 (0.41 to 26.81) Low Adverse effects Anticholinergic adverse effects Atypical probably reduces the chance of experiencing dry mouth, constipation, and blurred vision but often doses of the older drugs are such that these type of adverse effects are to be expected. Lower doses of control drug could have offset this risk. Data are based on moderate quality evidence. RR 0.2 (0.05 to 0.8) Moderate Leaving the study because of adverse effects Use of atypical drugs may increase the chance of leaving early because of adverse effects, but the difference between the treatments is not clear. Data supporting this finding are based on moderate quality evidence. RR 3.3 (0.41 to 26.81) Moderate Madaan et al. wrote that studies report efficacy of typical neuroleptics such as thioridazine, thiothixene, loxapine and haloperidol, high incidence of side effects such as extrapyramidal symptoms, akathisia, dystonias, sedation, elevated prolactin, tardive dyskinesia.
Childhood schizophrenia
Schizophrenia
Bipolar disorder in children
Autism spectrum
Multiple complex developmental disorder
Tardive dysmentia
Asperger syndrome
Pervasive developmental disorder not otherwise specified